Diagnostic and prognostic contribution of targeted NGS in patients with triple‐negative myeloproliferative neoplasms
Open Access
- 18 July 2019
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 94 (10) , E264-E267
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Primary myelofibrosis: 2019 update on diagnosis, risk‐stratification and managementAmerican Journal of Hematology, 2018
- Targeted deep sequencing in primary myelofibrosisBlood Advances, 2016
- Targeted deep sequencing in polycythemia vera and essential thrombocythemiaBlood Advances, 2016
- Application of an NGS‐based 28‐gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia veraBritish Journal of Haematology, 2016
- Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patientsBlood, 2016